The Pharmaceutical Benefits Advisory Committee (PBAC) has published its August 2026 update.
This update provides information on the special out of session meeting held on the 30 July 2026 to address the imminent delisting of the goserelin 3.6 mg implant (Zoladex Implant™) from the Pharmaceutical Benefits Scheme.